More MS news articles for Nov 2001

Anti-MOG and anti-MBP antibody subclasses in multiple sclerosis

http://www.ingenta.com/isis/searching/ExpandTOC/ingenta?issue=infobike://arn/ms/2001/00000007/00000005&index=3&WebLogicSession=O2A1TTLzRXDjqMzyZm8D|-2366265230036197976/-1052814329/6/7051/7051/7052/7052/7051/-1

Multiple Sclerosis,
October 2001, vol. 7, no. 5,   pp. 285-289(5)
Egg R. [1]; Reindl M. [1]; Deisenhammer F. [1]; Linington C. [2]; Berger T. [1] *
[1] Department of Neurology, University of Innsbruck, Anichstr. 35, A-6020 Innsbruck, Austria
[2] Department of Neuroimmunology, Max Planck Institute for Neurobiology, D-82152 Martinsried, Germany
[*] Correspondence: T Berger, University of Innsbruck, Department of Neurology, Anichstraße 35, A-6020 Innsbruck, Austria
 
Abstract:

In a subset of multiple sclerosis (MS) patients antibodies against myelin antigens seem to be important in the demyelinating process.

In this study we investigated IgM, IgA and IgG serum antibodies against the myelin oligodendrocyte glycoprotein (MOG) and the myelin basic protein (MBP) in 261 MS patients.

Seventy-two per cent had anti-MOG antibodies, 59% were anti-MBP seropositive.

The dominating antibody was anti-MOG IgM. A significant relationship between IgA and a progressive disease course was found.

The predominance of IgG1 together with the significantly associated occurrence of IgG3 against MOG corresponds to the prevailing IgG1 and IgG3 isotypes in other autoimmune diseases.

Patients who actually suffered from a relapse were significant more often anti-MOG and anti-MBP IgG3 seropositive than those in remission.

However, patients treated either with intravenous immunoglobulins or interferon-b showed a significant reduction of anti-MOG IgG3 antibodies.
 

© 2001 ingenta